Business Context and Reporting Period
This Form 8-K is filed by Nanoviricides, Inc., a Nevada corporation, with a report date of February 24, 2014. The filing addresses "Other Events" (Item 8.01) concerning insider trading activities and the subsequent disgorgement of profits by the company's President and Chairman, Dr. Anil Diwan.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only specific financial figure disclosed relates to a regulatory settlement:
- Disgorged Profits: $83,900 (repaid to the company on February 25, 2014).
- Shares Involved: 50,000 shares of Common Stock purchased by Dr. Diwan between February 18 and February 20, 2014.
Material Changes
The material event reported is the repayment of $83,900 to the company by Dr. Diwan. This payment was made to comply with Section 16(b) of the Securities Exchange Act of 1934, which mandates the disgorgement of "short-swing" profits realized by insiders from the purchase and sale (or sale and purchase) of company securities within a six-month period. Dr. Diwan had previously sold shares in October 2013 and repurchased 50,000 shares in February 2014.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of general operational risks. The primary contingency addressed is the legal requirement to return short-swing profits to the company, which has been resolved via the $83,900 repayment.
Investor Verification Checklist
- Verify the Form 4 filed on February 24, 2014, detailing Dr. Diwan's purchase of 50,000 shares.
- Confirm the receipt of the $83,900 disgorgement payment by the company.
- Review the press release dated February 26, 2014 (Exhibit 99.1) for additional context on the transaction.
- Note that this filing does not contain updated financial statements or operational results.